JPWO2022059692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022059692A5 JPWO2022059692A5 JP2023516476A JP2023516476A JPWO2022059692A5 JP WO2022059692 A5 JPWO2022059692 A5 JP WO2022059692A5 JP 2023516476 A JP2023516476 A JP 2023516476A JP 2023516476 A JP2023516476 A JP 2023516476A JP WO2022059692 A5 JPWO2022059692 A5 JP WO2022059692A5
- Authority
- JP
- Japan
- Prior art keywords
- dosing
- days
- week
- composition
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078844P | 2020-09-15 | 2020-09-15 | |
| US63/078,844 | 2020-09-15 | ||
| PCT/JP2021/033855 WO2022059692A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023541432A JP2023541432A (ja) | 2023-10-02 |
| JP2023541432A5 JP2023541432A5 (https=) | 2024-08-14 |
| JPWO2022059692A5 true JPWO2022059692A5 (https=) | 2024-08-14 |
| JP7828333B2 JP7828333B2 (ja) | 2026-03-11 |
Family
ID=80776678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516476A Active JP7828333B2 (ja) | 2020-09-15 | 2021-09-15 | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230390251A1 (https=) |
| EP (1) | EP4213842B1 (https=) |
| JP (1) | JP7828333B2 (https=) |
| KR (1) | KR20230067647A (https=) |
| AU (1) | AU2021345171A1 (https=) |
| TW (1) | TW202227060A (https=) |
| WO (1) | WO2022059692A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130005678A1 (en) * | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| US10889555B2 (en) * | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| US20200405697A1 (en) * | 2017-11-29 | 2020-12-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor Agent |
-
2021
- 2021-09-15 AU AU2021345171A patent/AU2021345171A1/en active Pending
- 2021-09-15 KR KR1020237012413A patent/KR20230067647A/ko active Pending
- 2021-09-15 JP JP2023516476A patent/JP7828333B2/ja active Active
- 2021-09-15 EP EP21869378.6A patent/EP4213842B1/en active Active
- 2021-09-15 TW TW110134368A patent/TW202227060A/zh unknown
- 2021-09-15 US US18/026,515 patent/US20230390251A1/en active Pending
- 2021-09-15 WO PCT/JP2021/033855 patent/WO2022059692A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022180461A5 (https=) | ||
| JP2021527092A5 (https=) | ||
| JP2005515966A5 (https=) | ||
| JPH06509809A (ja) | 短時間で医薬を放出する投与形態 | |
| AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
| JPWO2022059692A5 (https=) | ||
| ES2381794T3 (es) | Una composición de combinación que comprende ibuprofeno y paracetamol | |
| JPWO2020175629A5 (https=) | ||
| JPWO2022059691A5 (https=) | ||
| JPWO2019241442A5 (https=) | ||
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP2005501825A5 (https=) | ||
| JP2006503095A5 (https=) | ||
| RU2004131830A (ru) | Парентеральное, внутривенное и пероральное введение оксазолидинонов для лечения инфекционных поражений стопы при диабете | |
| CA2435921A1 (en) | Method of cancer therapy | |
| JP2022177119A5 (https=) | ||
| JP2021517128A5 (https=) | ||
| JPH06503806A (ja) | 胃腸疾病を処置するための５―ジフルオロメトキシ―２―［（３，４―ジメトキシ―２―ピリジル）メチルスルフィニル］ベンズイミダゾール及び抗ヘリコバクター剤含有医薬組成物 | |
| JPWO2020040806A5 (https=) | ||
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| RU2195937C1 (ru) | Комбинированный противотуберкулезный препарат (ризобутол) | |
| JP2009532494A (ja) | 高血圧処置のためのレニン阻害剤 | |
| RU2023109542A (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| JPWO2020000092A5 (https=) | ||
| CN1537006A (zh) | 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物 |